CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect

Affiliations

• ¹ Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, 21202, USA.
• ² Key Laboratory of Infection and Immunity of Shandong Province & Department of Immunology, School of Basic Medical Sciences, Shandong University, Jinan, 250012, China.
• ³ Shanghai Institute of Immunology, Department of Immunology and Microbiology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
• ⁴ Division of Oncology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA.
• ⁵ Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA, 95817, USA.
• ⁶ OncoC4, Inc, Rockville, MD, 20805, USA.
• ⁷ Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, 21202, USA. [email protected].
• ⁸ OncoC4, Inc, Rockville, MD, 20805, USA. [email protected].
• ⁹ Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, 21202, USA. [email protected].
• ¹⁰ OncoC4, Inc, Rockville, MD, 20805, USA. [email protected].